CN113677681A - Rsk抑制剂的结晶形式 - Google Patents

Rsk抑制剂的结晶形式 Download PDF

Info

Publication number
CN113677681A
CN113677681A CN202080027879.2A CN202080027879A CN113677681A CN 113677681 A CN113677681 A CN 113677681A CN 202080027879 A CN202080027879 A CN 202080027879A CN 113677681 A CN113677681 A CN 113677681A
Authority
CN
China
Prior art keywords
crystalline form
theta
compound
cancer
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080027879.2A
Other languages
English (en)
Chinese (zh)
Inventor
理查德·温尼克
伊莱恩·麦弗逊
埃里克·弗拉希夫
桑德拉·E·邓恩
乔纳森·洛克雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenix Molecular Designs Ltd
Original Assignee
Phoenix Molecular Designs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Molecular Designs Ltd filed Critical Phoenix Molecular Designs Ltd
Publication of CN113677681A publication Critical patent/CN113677681A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080027879.2A 2019-02-11 2020-02-10 Rsk抑制剂的结晶形式 Pending CN113677681A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804076P 2019-02-11 2019-02-11
US62/804,076 2019-02-11
PCT/IB2020/000092 WO2020165646A1 (en) 2019-02-11 2020-02-10 Crystalline forms of an rsk inhibitor

Publications (1)

Publication Number Publication Date
CN113677681A true CN113677681A (zh) 2021-11-19

Family

ID=72043971

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080027879.2A Pending CN113677681A (zh) 2019-02-11 2020-02-10 Rsk抑制剂的结晶形式

Country Status (9)

Country Link
US (1) US12378245B2 (https=)
EP (1) EP3924352A4 (https=)
JP (1) JP2022520382A (https=)
KR (1) KR20210126077A (https=)
CN (1) CN113677681A (https=)
AU (1) AU2020222056A1 (https=)
CA (1) CA3129722A1 (https=)
IL (1) IL285493A (https=)
WO (1) WO2020165646A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186098A (zh) * 2022-06-07 2023-12-08 上海科恩泰生物医药科技有限公司 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300246A1 (en) * 2005-08-09 2008-12-04 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
CN102573994A (zh) * 2009-08-06 2012-07-11 默克专利有限公司 新的双环脲化合物
WO2017105382A1 (en) * 2015-12-14 2017-06-22 Ryckman David M Crystalline forms of quinolone analogs and their salts
CN109071542A (zh) * 2016-02-19 2018-12-21 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4652697A (en) 1996-10-08 1998-05-05 Eli Lilly And Company New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0981327B1 (en) 1997-05-07 2002-11-06 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
US8765802B2 (en) 2007-06-12 2014-07-01 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
EP2200977B1 (en) 2007-09-14 2016-11-09 The Regents of the University of Michigan F1f0-atpase inhibitors and related methods
GB0718870D0 (en) 2007-09-27 2007-11-07 Univ Dundee Modulation of RSK
EP2509980A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Heterocyclic compounds containing an indole core
US9073926B2 (en) 2009-12-07 2015-07-07 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
WO2013181742A1 (en) 2012-06-04 2013-12-12 Phoenix Molecular Diagnostics Ltd. Methods of inhibiting rsk for treatment of breast cancer
CN103724251B (zh) 2014-01-18 2015-07-22 福州大学 一种靶向stat3的小分子化合物及其制备方法和应用
US9856258B2 (en) 2014-04-07 2018-01-02 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300246A1 (en) * 2005-08-09 2008-12-04 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
CN102573994A (zh) * 2009-08-06 2012-07-11 默克专利有限公司 新的双环脲化合物
WO2017105382A1 (en) * 2015-12-14 2017-06-22 Ryckman David M Crystalline forms of quinolone analogs and their salts
CN109071542A (zh) * 2016-02-19 2018-12-21 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
吕扬等: "《晶型药物》", vol. 1, 31 October 2009, 人民卫生出版社, pages: 6 - 7 *
朱贺敏等: "癌症靶标Aurora A激酶结构、功能与抑制剂研究进展", 《中国药学杂志》, vol. 48, no. 10, 31 May 2013 (2013-05-31), pages 753 - 758 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186098A (zh) * 2022-06-07 2023-12-08 上海科恩泰生物医药科技有限公司 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途
WO2023236960A1 (zh) * 2022-06-07 2023-12-14 上海科恩泰生物医药科技有限公司 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途
CN119451961A (zh) * 2022-06-07 2025-02-14 广州科恩泰生物医药科技有限公司 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
US20220112193A1 (en) 2022-04-14
US12378245B2 (en) 2025-08-05
JP2022520382A (ja) 2022-03-30
EP3924352A4 (en) 2022-11-16
KR20210126077A (ko) 2021-10-19
AU2020222056A1 (en) 2021-10-07
IL285493A (en) 2021-09-30
WO2020165646A1 (en) 2020-08-20
EP3924352A1 (en) 2021-12-22
CA3129722A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
CN113677681A (zh) Rsk抑制剂的结晶形式
US11739102B2 (en) Fused pyrimidine compounds as KRAS inhibitors
US11999752B2 (en) Vinyl imidazole compounds as inhibitors of KRAS
CN114258318B (zh) 氨基嘧啶酰胺自噬抑制剂及其使用方法
ES2981114T3 (es) 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios
US10501437B2 (en) Crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
EP3261631B1 (en) Inhibition of olig2 activity
JP7758369B2 (ja) Ｇａｓ４１阻害剤及びその使用方法
AU2017314842B2 (en) Inhibition of Olig2 activity
US12084453B2 (en) Bicyclic amines as CDK12 inhibitors
US20140275234A1 (en) Compositions and methods of using crystalline forms of wortmannin analogs
TW202547837A (zh) 噻吩并－三唑并－二氮呯醋酸酯
US20240116877A1 (en) Kit kinase inhibitors and methods of use thereof
US20250353842A1 (en) Bicyclic amine cdk12 inhibitors
US20260098044A1 (en) Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1
HK40078032A (en) Solid state crystalline forms of a selective potassium channel modulator
HK1221468B (zh) 酞嗪衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211119

WD01 Invention patent application deemed withdrawn after publication